Bardin Hill Management Partners LP Has $17.21 Million Stock Holdings in Axonics, Inc. (NASDAQ:AXNX)

Bardin Hill Management Partners LP boosted its position in shares of Axonics, Inc. (NASDAQ:AXNX) by 134.2% during the third quarter, Holdings Channel.com reports. The fund owned 247,233 shares of the company’s stock after acquiring an additional 141,688 shares during the quarter. Axonics accounts for 8.0% of Bardin Hill Management Partners LP’s investment portfolio, making the stock its 2nd largest holding. Bardin Hill Management Partners LP’s holdings in Axonics were worth $17,207,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in shares of Axonics by 0.9% during the 2nd quarter. AQR Capital Management LLC now owns 18,337 shares of the company’s stock valued at $1,233,000 after buying an additional 161 shares in the last quarter. Xponance Inc. lifted its position in shares of Axonics by 7.5% in the second quarter. Xponance Inc. now owns 3,231 shares of the company’s stock valued at $217,000 after acquiring an additional 225 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Axonics by 2.5% in the second quarter. Arizona State Retirement System now owns 14,278 shares of the company’s stock worth $960,000 after acquiring an additional 355 shares during the period. FMR LLC boosted its stake in shares of Axonics by 2.5% in the third quarter. FMR LLC now owns 31,756 shares of the company’s stock worth $2,210,000 after acquiring an additional 769 shares during the period. Finally, Mercer Global Advisors Inc. ADV grew its position in shares of Axonics by 12.7% during the second quarter. Mercer Global Advisors Inc. ADV now owns 6,981 shares of the company’s stock worth $469,000 after purchasing an additional 785 shares in the last quarter. Hedge funds and other institutional investors own 99.48% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reissued a “hold” rating on shares of Axonics in a report on Friday, November 8th. Eight research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $71.00.

Insider Buying and Selling at Axonics

In other news, CFO Kari Leigh Keese sold 2,961 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total value of $205,523.01. Following the sale, the chief financial officer now directly owns 40,362 shares in the company, valued at approximately $2,801,526.42. This trade represents a 6.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.85% of the stock is owned by insiders.

Axonics Stock Performance

NASDAQ:AXNX opened at $70.98 on Monday. The firm has a 50-day simple moving average of $70.28 and a 200-day simple moving average of $68.84. Axonics, Inc. has a one year low of $55.09 and a one year high of $71.05. The firm has a market cap of $3.63 billion, a P/E ratio of -591.45 and a beta of 0.82.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.